+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05469893

Immuno-PRISM Phase II Study Comparing Teclistamab versus Lenalidomide Plus Dexamethasone in Adults with High-Risk Smoldering Multiple Myeloma

Led by Irene Ghobrial, MD · Updated on 2026-07-16

52

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the anti-cancer activity of Teclistamab compared to a combination of Lenalidomide and Dexamethasone in adults with high-risk smoldering multiple myeloma SMM. SMM is an early form of multiple myeloma, a cancer of plasma cells, where patients often have no symptoms but are at risk of progression to active multiple myeloma. Currently, there are no approved treatments for smoldering multiple myeloma, so this study aims to explore potential therapies. This phase II randomized study includes multiple arms where participants will receive either Teclistamab or the combination of Lenalidomide plus Dexamethasone. Initially, a safety run-in phase will enroll up to six participants in the Teclistamab arm to evaluate its safety at different doses. After confirming safety, participants will be randomized in a 12 ratio to either the control arm with Lenalidomide plus Dexamethasone or the Teclistamab arm. Each treatment cycle lasts 28 days and the study drugs will be given as per protocol through intravenous or oral routes, continuing up to 24 months or until disease progression. Participants will undergo screening before enrollment, followed by treatment and then end-of-treatment assessments and long-term follow-up. Throughout the study, multiple evaluations will be conducted including blood tests, bone marrow assessments, and biomarker studies to monitor response, disease progression, and safety. Primary outcomes focus on complete response rates, while secondary outcomes include minimal residual disease negativity, progression-free survival, and treatment-emergent adverse events, with follow-up extending up to five years after treatment ends.

CONDITIONS

Brief Title

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Research Team

I

Irene Ghobrial, MD

A

Ashlee Sturtevant, MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here